Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RecoSeel is a fully recombinant fibrin sealant being developed by Fibriant B.V. for use as a topical hemostat in surgical procedures to control mild-to-moderate bleeding. The product consists of two main components: a recombinant human fibrinogen variant and recombinant human thrombin. When applied to a surgical site, the thrombin component triggers the conversion of the fibrinogen variant into an insoluble fibrin matrix, mimicking the final step of the natural blood coagulation cascade to form a stable clot. Unlike traditional fibrin sealants derived from human plasma, RecoSeel's recombinant nature offers a more controlled manufacturing process, a reduced risk of viral or prion contamination, and a more consistent supply chain. It is designed for topical application during surgery to achieve rapid hemostasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RecoSeel.